medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2011, Número 3

<< Anterior Siguiente >>

Acta Med 2011; 9 (3)


Neumonía necrotizante hemorrágica y SARM-AC como causa emergente

Rojo EA, Videgaray OF, Raffoul CI

Idioma: Español
Referencias bibliográficas: 59
Paginas: 143-148
Archivo PDF: 86.96 Kb.


RESUMEN

Staphylococcus aureus ha sido reconocido como una causa de neumonía adquirida en la comunidad. La neumonía por S. aureus resistente a meticilina (SARM) se ha limitado a hospitales, principalmente a neumonía asociada a cuidados de la salud y a ventilación mecánica. En 1999, cuatro muertes pediátricas fueron reportadas secundarias a neumonía necrotizante por SARM adquirido en la comunidad (SARM-AC). Estas infecciones fueron causadas por cepas que difieren de las típicas cepas nosocomiales de acuerdo a sus patrones de sensibilidad a los antibióticos y a la electroforesis en campo pulsado (PFGE). En 2002, se encontró una asociación entre la presencia de leucocidina Panton-Valentine (PVL) una toxina estafilocócica asociada con necrosis de tejido y este síndrome descrito previamente de neumonía necrotizante hemorrágica aguda en los individuos sanos que presentan neumonía estafilocócica de la comunidad. Presentamos el caso de un paciente con neumonía necrotizante por SARM-AC, así como revisión de los orígenes, fisiopatogenia, manifestaciones clínicas y opciones de tratamiento para esta entidad emergente.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bradley SF. Staphylococcus aureus pneumonia: emergence of MRSA in the community. Semin Respir Crit Care Med 2005; 26: 643-649.

  2. Laupland KB, Church DL, Mucenski M, Sutherland LR, Davies HD. Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis 2003; 187: 1452-1459.

  3. Lynch J. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 2001; 119(Suppl 2): 373S–384S. Kollef MH, 4.

  4. Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128: 3854-3862.

  5. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus, Minnesota and North Dakota, 1997–1999. MMWR Morb Mortal Wkly Rep 1999; 48: 707-710.

  6. Naimi TS, LeDell KH, Boxrud DJ et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001; 33: 990-996.

  7. Gillet Y, Issartel B, Vanhems P et al. Association between Staphyloccocus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359: 753-759.

  8. Udo EE, Pearman JW, Grubb WB. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 1993; 25: 97-108.

  9. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison, Mississippi, 2000. MMWR Morb Mortal Wkly Rep 2001; 50: 919-922.

  10. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus infections among competitive sports participants: Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep 2003; 52: 793-795.

  11. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus infections in correctional facilities: Georgia, California, and Texas, 2001-2003. MMWR Morb Mortal Wkly Rep 2003; 52: 992-996.

  12. Jones TF, Creech CB, Erwin P, Baird SG, Woron AM, Schaffner W. Family outbreaks of invasive community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2006; 42: e76–78.

  13. Zafar U, Johnson LB, Hanna M et al. Prevalence of nasal colonization among patients with community-associated methicillin-resistant Staphylococcus aureus infection and their household contacts. Infect Control Hosp Epidemiol 2007; 28: 966-969.

  14. Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S aureus infections among patients in the emergency department. N Engl J Med 2006; 355: 666-674.

  15. Vandenesch F, Naimi T, Enright MC et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003; 9: 978-984.

  16. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006; 144: 309-317.

  17. Wallin TR, Hern HG, Frazee BW. Community-associated methicillin-resistant Staphylococcus aureus. Emerg Med Clin North Am 2008; 26: 431-455.

  18. Klevens RM, Morrison MA, Nadle J et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298: 1763-1771.

  19. Ito T, Katayama Y, Asada K et al. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45: 1323-1336.

  20. Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, Staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44: 1549-1555.

  21. Zhang K, McClure JA, Elsayed S, Louie T, Conly JM. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43: 5026-5033.

  22. Deurenberg RH, Stobberingh EE. The evolution of Staphylococcus aureus. Infect Genet Evol 2008; 8: 747-763.

  23. Ma XX, Ito T, Tiensasitorn C et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002; 46: 1147-1152.

  24. Lina G, Piemont Y, Godail-Gamot F et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29: 1128-1132.

  25. Naimi TS, LeDell KH, Como-Sabetti K et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290: 2976-2984.

  26. Tristan A, Bes M, Meugnier H et al. Global distribution of Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus, 2006. Emerg Infect Dis 2007; 13: 594-600.

  27. Centers for Disease Control and Prevention. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza; Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56: 325-329.

  28. Boussaud V, Parrot A, Mayaud C et al. Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus. Intensive Care Med 2003; 29: 1840-1843.

  29. Francis JS, Doherty MC, Lopatin U et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40: 100-107.

  30. Gillet Y, Vanhems P, Lina G et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007; 45: 315-321.

  31. Garnier F, Tristan A, Francois B et al. Pneumonia and new methicillin-resistant Staphylococcus aureus clone. Emerg Infect Dis 2006; 12: 498-500.

  32. Dufour P, Gillet Y, Bes M et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002; 35: 819-824.

  33. Hageman JC, Uyeki TM, Francis JS et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12: 894-899.

  34. de Bentzmann S, Tristan A, Etienne J, Brousse N, Vandenesch F, Lina G. Staphylococcus aureus isolates associated with necrotizing pneumonia bind to basement membrane type I and IV collagens and laminin. J Infect Dis 2004; 190: 1506-1515.

  35. Davison VE, Sanford BA. Adherence of Staphylococcus aureus to influenza A virus-infected Madin-Darby canine kidney cell cultures. Infect Immun 1981; 32: 118-126.

  36. Finck-Barbancon V, Duportail G, Meunier O, Colin DA. Pore formation by a two-component leukocidin from Staphylococcus aureus within the membrane of human polymorphonuclear leukocytes. Biochim Biophys Acta 1993; 1182: 275-282.

  37. Ward PD, Turner WH. Identification of staphylococcal Panton-Valentine leukocidin as a potent dermonecrotic toxin. Infect Immun 1980; 28: 393-397.

  38. Gomez MI, Lee A, Reddy B et al. Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1. Nat Med 2004; 10: 842-848.

  39. Genestier AL, Michallet MC, Prevost G et al. Staphylococcus aureus Panton-Valentine leukocidin directly targets mitochondria and induces Bax-independent apoptosis of human neutrophils. J Clin Invest 2005; 115: 3117-3127.

  40. Labandeira-Rey M, Couzon F, Boisset S et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007; 315: 1130-1133.

  41. Wardenburg JB, Bae T, Otto M, Deleo FR, Schneewind O. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 2007; 13: 1405-1406.

  42. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2): S27-72.

  43. Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 2000; 16(Suppl 1): S31-34.

  44. Geisel R, Schmitz FJ, Thomas L et al. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area. J Antimicrob Chemother 1999; 43: 846-848.

  45. Skrupky LP, Micek ST, Kollef MH. Optimizing therapy for MRSA pneumonia. Semin Respir Crit Care Med 2007; 28: 615-623.

  46. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25: 980-992.

  47. Powers JH, Ross DB, Lin D, Soreth J. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses. Chest 2004; 126: 314-316.

  48. Powers JH, Lin D, Ross D. FDA evaluation of antimicrobials: subgroup analysis. Chest 2005; 127: 2298-2301.

  49. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149-2152.

  50. Ge Y, Biek D, Talbot GH, Sahm DF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008; 52: 3398-3407.

  51. Wenzel RP, Bearman G, Edmond MB. Community-acquired methicillin-resistant Staphylococcus aureus (MRSA): new issues for infection control. Int J Antimicrob Agents 2007; 30: 210-212.

  52. van Langevelde P, van Dissel JT, Meurs CJ, Renz J, Groeneveld PH. Combination of flucloxacillin and gentamicin inhibits toxic shock syndrome toxin 1 production by Staphylococcus aureus in both logarithmic and stationary phases of growth. Antimicrob Agents Chemother 1997; 41: 1682-1685.

  53. Gemmell CG, O’Dowd A. Regulation of protein A biosynthesis in Staphylococcus aureus by certain antibiotics: its effect on phagocytosis by leukocytes. J Antimicrob Chemother 1983; 12: 587-597.

  54. Gemmell CG, Ford CW. Virulence factor expression by Gram-positive cocci exposed to subinhibitory concentrations of linezolid. J Antimicrob Chemother 2002; 50: 665-672.

  55. Dumitrescu O, Boisset S, Badiou C et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother 2007; 51: 1515-1519.

  56. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195: 202-211.

  57. Gauduchon V, Cozon G, Vandenesch F et al. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis 2004; 189: 346-353.

  58. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med 2001; 344: 11-16.

  59. Ellis MW, Hospenthal DR, Dooley DP, Gray PJ, Murray CK. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis 2004; 39: 971-979.




2020     |     www.medigraphic.com